Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Repository of the University of Ljubljana
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Advanced
New in RUL
About RUL
In numbers
Help
Sign in
Details
Bleomycin electrosclerotherapy (BEST) : mechanistic parallels to electrochemotherapy, experimental models, and unresolved questions
ID
Lisec, Barbara
(
Author
),
ID
Čemažar, Maja
(
Author
),
ID
Muir, Tobian
(
Author
),
ID
Omerzel, Maša
(
Author
),
ID
Jesenko, Tanja
(
Author
),
ID
Markelc, Boštjan
(
Author
),
ID
Grošelj, Aleš
(
Author
),
ID
Dežman, Rok
(
Author
),
ID
Štabuc, Miha
(
Author
),
ID
Kuhelj, Dimitrij
(
Author
),
ID
Serša, Gregor
(
Author
)
PDF - Presentation file,
Download
(2,26 MB)
MD5: C2E86E8FD336E838C5F05933CE0E95A8
URL - Source URL, Visit
http://dx.doi.org/10.2478/raon-2026-0017
Image galllery
Abstract
Background. Bleomycin electrosclerotherapy (BEST) is an emerging treatment option for vascular malformations (VMs), predominantly slow-flow venous malformations, with increasing use in other types of VMs. By combining application of bleomycin with electroporation, BEST enhances intracellular drug delivery and may improve treatment efficacy while allowing the use of lower drug doses. Although clinical evidence supporting its efficacy is growing, the biological mechanisms underlying these effects remain poorly understood. Key unresolved questions include endothelial responses to BEST, what are the dominant mechanisms of vascular injury and remodeling, and how hemodynamics and abnormal vessel architecture affect bleomycin distribution, pharmacokinetics, and effective dosing within the lesion. Although the clinical effects of BEST may be similar to the vascular disrupting effect of electrochemotherapy, it remains unclear whether these vascular mechanisms are in fact the same. Conclusions. Understanding, how bleomycin is delivered, distributed, and retained within VM tissue, and how this interacts with endothelial susceptibility and electroporation efficiency, will be essential for defining optimal dosing strategies. Addressing these questions will require experimental approaches and physiologically relevant models capable of capturing the genetic, structural, and hemodynamic features of VMs. Such advances will be critical for elucidating the mechanisms of BEST and optimizing its clinical application.
Language:
English
Keywords:
vascular malformations
,
bleomycin electrosclerotherapy
,
BEST
,
electrochemotherapy
Work type:
Article
Typology:
1.02 - Review Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2026
Number of pages:
14 str.
Numbering:
Vol. 60, iss. 1
PID:
20.500.12556/RUL-181360
UDC:
616-006
ISSN on article:
1581-3207
DOI:
10.2478/raon-2026-0017
COBISS.SI-ID:
271953155
Publication date in RUL:
03.04.2026
Views:
82
Downloads:
22
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Radiology and oncology
Publisher:
Association of Radiology and Oncology
ISSN:
1581-3207
COBISS.SI-ID:
784507
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Projects
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
P3-0003
Name:
Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev
Funder:
Institut of Oncology Ljubljana
Project number:
OI-8-24
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back